Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: GLP-1/FGF21 dual-agonist mRNA, GLP-1/IgG4 Fc/FGF21 tri-cistronic mRNA, GIFT mRNA, mRNA-encoded GLP-1/FGF21 fusion protein
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
mGLP-1/FGF21 is a research designation for modified messenger RNA encoding a bifunctional fusion protein that engages the GLP-1 receptor and the FGF21 signaling pathway. The reported construct contains a GLP-1 analog, an IgG4 Fc stability and half-life-extension element, and an engineered FGF21 variant. In the primary 2026 study, the mRNA was formulated in a lipid nanoparticle designed for preferential delivery to adipose tissue and was evaluated in cell-based assays and obese mouse models. The construct is experimental and has not been established as an approved therapeutic or as a standardized chemical entity.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence reviewed concerns an mRNA-loaded lipid nanoparticle formulation and its expressed fusion protein, not an isolated catalog-grade compound. The primary study reported a single 0.67 mg/kg mRNA subcutaneous administration for pharmacokinetic assessment and a weekly dosing interval in a ten-week mouse prevention experiment; these are study-specific preclinical parameters and are not validated dosing recommendations. Common reference sizes are not an appropriate standardized catalog fact for this mRNA/LNP construct. Related GLP-1/FGF21 recombinant fusion proteins reported in other studies are distinct constructs and should not be treated as identical to mGLP-1/FGF21.
Supplementary research context only. Not medical advice or a treatment recommendation.
DOI: 10.1002/advs.202517672; PMID: 41431190; PMCID: PMC12915099
The designation is not a standardized nonproprietary name and refers to an mRNA therapeutic construct rather than a single small-molecule compound or purified peptide. Reported evidence is preclinical. The study evaluated GLP-1/FGF21 mRNA constructs containing either a VLK or IgG4 Fc linker; the optimized construct was designated GLP-1/IgG4 Fc/FGF21 tri-cistronic mRNA, or GIFT mRNA. No human clinical efficacy, pharmacokinetic, safety, or regulatory data were identified for this exact mRNA construct.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention mGLP-1/FGF21 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.